ImpediMed Names Erik Anderson as New Chief Executive Officer Amid Business Expansion

ImpediMed Appoints Erik Anderson as CEO

ImpediMed, a prominent name in medical technology, has recently taken a significant step forward by naming Erik Anderson as its Chief Executive Officer. This strategic move arrives at a crucial time, as the company focuses on enhancing its operations and expanding its reach within the healthcare community. Anderson, who joined the company's Board of Directors in February 2026, will officially assume his role on April 7, 2026, and will succeed Dr. Parmjot Bains, who has led the company through transformative periods.

Anderson's appointment is particularly timely as ImpediMed's Breast Cancer Related Lymphedema (BCRL) business shows promising growth. The Board of Directors recognized that advancing to the next level of commercial execution was essential, especially in the competitive landscape of the U.S. healthcare market. Anderson's leadership will be vital in achieving revenue growth, enhancing health system adoption, managing costs efficiently, and steering the company towards long-term profitability.

With a wealth of experience in the medical technology sector, Anderson has a robust background in commercial leadership. His most recent position was as President of the Breast and Skeletal Health Division at Hologic, a global front-runner in breast cancer care. He played a pivotal role in the growth of one of their largest business units, overseeing operations that generated significant revenue and cultivating relationships with key health system stakeholders.

His expertise also extends to healthcare delivery dynamics, encompassing hospital sales, clinical adoption strategies, and reimbursement processes. This makes Anderson exceptionally well-equipped to guide ImpediMed's growth initiatives related to BCRL, body composition monitoring, and heart health solutions.

Anderson expressed enthusiasm about joining ImpediMed, stating, "This company is positioned to play a vital role in cancer survivorship and has immense potential to grow from its current standing. My focus will be on delivering exceptional value for patients and their caregivers, while also ensuring a strong return on investment for our shareholders." This promise reflects his dedication to the company's mission of improving patient care through innovative technology.

In the two years leading up to this transition, ImpediMed has built a solid operational foundation aimed at sustainable growth. Under Dr. Bains' leadership, the company broadened its market reach by introducing new clinical applications on the SOZO® platform, focusing on body composition monitoring for weight management and fluid status assessments for heart health. This expansion is complemented by significant improvements in BCRL reimbursement coverage, which now encompasses 93% of covered lives in the U.S., positioning the company for substantial market opportunities.

Dr. Bains will remain with ImpediMed until June 30, 2026, in an advisory capacity to ensure a seamless transition for Anderson. This strategic partnership between the outgoing and incoming leadership is expected to foster continuity while paving the way for innovative advancements within the company.

ImpediMed, renowned for its innovative bioimpedance spectroscopy (BIS) devices, provides real-time insights to clinicians for personalized patient care. The SOZO® Digital Health Platform and L-Dex® are pioneering technologies in the non-invasive monitoring of fluid status and tissue composition, specifically for patients at risk of secondary lymphedema, notably those affected by breast cancer. This not only enhances the quality of care but also supports structured cancer survivorship programs and medical weight management efforts.

The company is recognized globally by healthcare organizations and research institutions for its impactful contributions to the monitoring and management of body fluid and tissue health across various care pathways. As Anderson steps into his new role, all eyes will be on ImpediMed to see how it navigates the evolving medical landscape and continues to redefine patient care services.

For further information about ImpediMed's initiatives and technology offerings, please visit ImpediMed's official website.